אקסטביה

Nchi: Israeli

Lugha: Kiebrania

Chanzo: Ministry of Health

Viambatanisho vya kazi:

INTERFERON BETA 1B 0.3 MG

Inapatikana kutoka:

NOVARTIS PHARMA SERVICES AG

ATC kanuni:

L03AB08

Dawa fomu:

POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Njia ya uendeshaji:

S.C

Viwandani na:

BAYER PHARMA AG, GERMANY

Kundi la matibabu:

INTERFERON BETA-1B

Matibabu dalili:

Extavia is indicated for the treatment of:• For use in relapsing-remitting and relapsing-progressive multiple sclerosis. It is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite MS, and who have experienced at least two exacerbations over the last two years.Extavia reduces the frequency of clinical exacerbations.In secondary progressive multiple sclerosis Extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. Compared with placebo, patients receiving Extavia showed a statistically significant delay in time to progression of multiple sclerosis. The treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). Patients receiving Extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. See also Section 5.1 “Pharm

Idhini ya tarehe:

2011-07-01